louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02113488: Causes of Nonattendance at Scheduled Outpatient Appointments
Official title: Case-control Study: Causes of Nonattendance at Clinical Medicine Scheduled Outpatient Appointments in a University General Hospital
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Appointments and Schedules
Outpatient Clinics, Hospital
Lead sponsor: Hospital Italiano de Buenos Aires
Sponsor class: OTHER
First posted: 2014-04-14
Enrollment: 450
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adults with a scheduled appoitment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)

Brief summary: Our aim was to identify the causes non-attendance at scheduled appointments at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA).

Detailed description: Nonattendance at scheduled appointments at outpatient clinics is a common problem in general medical practice, representing a significant cost to the health care system, and resulting in disruption of daily work planning.Nonattendance at medical appointments has consequences not only for doctors (as it requires a greater use of resources and time), but also for patients, because there may be deterioration in the quality of care, and dissatisfaction associated with delays in obtaining a new appointment.

Eligibility criteria: Inclusion Criteria:

* Over 17 years
* Adults who attended, did not attend and cancelled a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)

Exclusion Criteria:

* Refusal to register or to the informed consent process

Primary outcomes:
measure: Causes of nonattendance
timeFrame: Between the scheduled appointment and 48 hours after
Secondary outcomes:
measure: Causes of cancelation
timeFrame: Between the scheduled appointment and 48 hours after
Other outcomes:
Locations:
city: Capital Federal
country: Argentina
facility: Hospital Italiano de Buenos Aires
Study officials:
affiliation: Hospital Italiano de Buenos Aires (HIBA)
name: Diego H Giunta, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05740488: Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases
Official title: Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Prostate Cancer With ≤10 Bone Metastases
Lead sponsor: Zhujiang Hospital
Sponsor class: OTHER
First posted: 2023-02-23
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the efficacy and safety of apalutamide in combination with 89Sr as neoadjuvant therapy in prostate cancer with ≤10 bone metastases. The primary endpoint is PFS and the second endpoints are pCR, rPFS, PSA response, pain score, number and extent of bone metastases.


Eligibility criteria: Inclusion Criteria:

1. Prostate cancer confirmed by pathological findings;
2. Bone metastasis confirmed by bone scan, the number of bone metastases ≤10
3. Agreement to undergo laparoscopic radical prostatectomy + pelvic lymphadenectomy;
4. ECOG score of 0 - 1
5. Agreement to undergo preoperative and postoperative endocrine therapy and 89Sr radionuclide therapy;
6. Voluntary signing of an ICF for the clinical trial

Exclusion Criteria:

1. Any other tumor disease requiring treatment;
2. Any organ metastasis confirmed by imaging, such as liver and brain metastases, or the possibility of paralysis due to spinal cord metastasis;
3. A history of epilepsy or any condition that may lead to seizures;
4. Severe liver or kidney dysfunction, severe cardiovascular or cerebrovascular diseases, and systemic immune system diseases

Primary outcomes:
measure: PFS
timeFrame: Up to 2 years after radical prostatectomy
Secondary outcomes:
measure: pCR
timeFrame: Up to 1 year
measure: rPFS
timeFrame: Up to 3 years
measure: PSA response rate
timeFrame: Up to 3 years
measure: pain score
timeFrame: Measured at baseline and follow up visits throughout the study, an average of 3 years
measure: number and extent of bone metastases
timeFrame: Up to 3 years
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: zhujiang Hospital of Southern Medical University
state: Guangdong
Study officials:
affiliation: Southern Medical University, China
name: Chen Binshen
role: STUDY_CHAIR
References:
Clinical trial NCT02005588: Treatment of Iron Deficiency Anemia With Pregnancy
Official title: Comparison Between Aminoacid Chelated Iron and Iron Salt in Treatment of Iron Deficiency Anemia With Pregnancy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Iron Deficiency Anemia of Pregnancy
Keywords: amino acid chelated iron
iron salt
iron deficiency anemia
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2013-12-09
Enrollment: 150
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Iron deficiency anemia is a very common problem accompanying pregnancy. in this study, the investigators are going to compare the efficacy and tolerability of two preparations of oral iron in treatment of iron deficiency anemia with pregnancy.

Detailed description: In this study, the investigators are going to compare two preparations of oral iron in treatment of iron deficiency anemia with pregnancy. a total of 300 pregnant women will be randomly divided into two equal groups (each containing 150 pregnant woman). one group will receive amino acid chelated iron and the other group will receive iron salt (ferrous fumarate). All pregnant women attending the obstetrics outpatient clinic of kasr al aini hospital at 14-18 weeks gestation will be submitted to complete blood picture and serum ferritin. those who prove to have iron deficiency anemia (hemoglobin less than 11g/dl and serum ferritin less than 12ug/l) will be included in the study. All eligible women will be followed up at 22-23, 29-30 and 36-37 weeks' gestation for the change in hemoglobin level and ferritin level. all women will be also enquired about different side effects during treatment period.

Eligibility criteria: Inclusion Criteria:

* Age: 20-40 years
* Pregnant 14-18 weeks
* Singleton fetus
* Hb 7-10.9 g/dl
* Serum ferritin \<12 microgram/L

Exclusion Criteria:

* history of anemia due to other causes as chronic blood loss, hemolytic anemia or thalassemia
* Multiple pregnancy
* known hepatic, renal or cardiovascular abnormality.
* Known peptic ulcer, esophagitis, gastritis or hiatus hernia.
* Family history of thalassemia, sickle cell anemia, or malabsorption syndrome.
* Iron preparation intake within 24 hours of inclusion

Primary outcomes:
measure: change in hemoglobin level
timeFrame: 6 months
Secondary outcomes:
measure: the occurence of side effects (abdominal colics, constipation, or metallic taste)
timeFrame: 6 months
measure: change in serum ferritin level
timeFrame: 6 months
Other outcomes:
measure: cost of treatment
timeFrame: 6 months
Locations:
city: Cairo
country: Egypt
facility: faculty of medicine, Cairo University
Study officials:
affiliation: Cairo University
name: Ahmed M Sayed, professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT02547688: Assessment of the Tolerability of Dry Airflow in the Nasal Cavity During Sleep
Official title: Assessment of the Tolerability of Dry Airflow in the Nasal Cavity During Sleep
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Healthy Adults
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
First posted: 2015-09-11
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Preliminary data show that high flow nasal air has been shown to reduce promote heat exchange due to evaporation of nasal mucus by the air flow resulting in heat loss. It is unclear whether unidirectional nasal airflow is well tolerated in healthy individuals. The central hypothesis of this proposal is that dry high flow nasal air will be sufficiently tolerated in healthy adults.


Eligibility criteria: Inclusion Criteria:

* Healthy men and women
* Able to consent
* Age ≥ 18
* BMI\<30kg/m2

Exclusion Criteria:

* Previous diagnosis of obstructive sleep apnea or sleep disorder
* History of Constant Positive Airway Pressure treatment for Obstructive Sleep Apnea
* History of recurrent epistasis
* Pregnancy (self-report)
* Deviated nasal septum
* Unstable cardiovascular disease (decompensated Congestive Heart Failure, myocardial infarction or revascularization procedures, unstable arrhythmias)
* Uncontrolled hypertension with BP \> 190/110
* Daytime hypoxemia with oxygen saturation\<90% (measured at history and physical examination)
* Supplemental oxygen use
* Work in transportation industry as a driver or pilot.

Primary outcomes:
measure: Subjective Tolerability using Questionnaire
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins University
state: Maryland
Study officials:
affiliation: Johns Hopkins University
name: Jason Kirkness, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03461588: Prospective Assessment of Radiation-induced Heart Injury in Left-sided Breast Cancer
Official title: Prospective Assessment of Radiation-induced Heart Injury in Left-sided Breast Cancer Treated With Breast Conserving Surgery Followed by Radiotherapy With Free-breathing or Deep Inspiration Breath-hold (DIBH) Technique
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Neoplasms
Heart Injuries
Radiation Toxicity
Lead sponsor: ChineseAMS
Sponsor class: UNKNOWN
First posted: 2018-03-12
Enrollment: 140
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is to prospectively investigate the cardiac dose-sparing effect and clinical benefit of deep inspiration breath-hold (DIBH) technique. Patients with left-sided breast cancer treated with breast conserving surgery followed by radiotherapy is enrolled. Radiotherapy is delivered with either free-breathing or deep inspiration breath-hold (DIBH) technique. The cardiac dose parameters and cardiac toxicity are prospective evaluated, and the dose-effect relationship is analyzed.

Detailed description: Patients with left-sided breast cancer treated with breast conserving surgery are prospectively enrolled. Two types of radiation treatment are delivered based on attending physician's preferences: radiation to whole breast +- regional nodal areas with free-breathing technique, or with deep inspiration breath-hold (DIBH) technique. The cardiac dose parameters including heart dose and the dose to left anterior coronary artery are assessed, and the cardiac toxicities regularly assessed with cardiac enzymes,electrocardiogram(ECG) and normal gated single-photon emission computed tomography-myocardial perfusion imaging before, during and after radiation.The dose-effect relationship of heart injuries is analyzed.

Eligibility criteria: Inclusion Criteria:

1. Left-sided breast cancer
2. Underwent breast conserving surgery
3. Planned for postoperative whole breast +- regional nodal radiotherapy
4. No basic heart disease

Exclusion Criteria:

1. Abnormal cardiac baseline examination
2. History of chest radiation
3. Can not tolerate deep inspiratory breath-holding

Primary outcomes:
measure: Number of participants with treatment-related cardiac adverse events as assessed by CTCAE v4.0
timeFrame: up to 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Cancer Hospital, Chinese Academy of Medical Sciences
city: Beijing
country: China
facility: Cancer Hosptical, Chinese Academy of Medical Sciences
Study officials:
affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
name: Shulian Wang, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03928509: Cohort as Part of Undergraduate Medical Studies at the University of Sherbrooke
Official title: Cohort as Part of Undergraduate Medical Studies at the University of Sherbrooke
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Public Health
Lead sponsor: Université de Sherbrooke
Sponsor class: OTHER
First posted: 2019-04-26
Enrollment: 6000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The target population is everyone who has been diagnosed with covid-19 in several regions in Quebec

Brief summary: The main goals of this project are to support the research training of undergraduate medical students at the University de Sherbrooke and promote planning of health services a better knowledge of the prevalence, social, and geographic distribution of public health issues in several regions in Quebec.

To meet the objectives of the project, a population-based prospective study linked to several regions in Quebec public health surveys is proposed.

Monitoring and data collection will be provided by 3rd year undergraduate medical students at University de Sherbrooke through telephone interviews.

The research themes will be proposed by various researchers affiliated with the University de Sherbrooke. They will be selected yearly by an internal scientific committee and included in the questionnaires administered by the students.


Eligibility criteria: Inclusion criteria:

* Participants will have been diagnosed with covid-19 between November 2020 and May 2021;
* Place of residence: province of Quebec.

Exclusion criteria :

- Unfit adults.

Primary outcomes:
measure: Health questionnaire
timeFrame: Once a year through study completion.
Secondary outcomes:
Other outcomes:
Locations:
city: Sherbrooke
country: Canada
facility: Centre Hospitalier Universitaire de Sherbrooke, departement de médecine
state: Quebec
Study officials:
affiliation: Université de Sherbrooke
name: Paul Farand, MD MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04010409: Mindreading in Adults With Autism Spectrum Disorder
Official title: Mindreading in Adults With Autism Spectrum Disorder
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Autism Spectrum Disorder
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2019-07-08
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The 30 adults with ASD will be recruited from Adult ASD clinics in Department of Psychiatry, National Taiwan University Hospital.

Brief summary: This study aims to investigate the ability of reading emotions by the Eyes task in adults with ASD, and examine the gazing pattern and frontal activation during the task. We plan to recruit 50 adults with ASD and 50 typically-developing adults. Eye-tracking and frontal activation (measured by functional near-infrared spectroscopy) will be examined during the Eyes task.

Detailed description: Autism spectrum disorder (ASD) is a clinical syndrome characterized by mindreading deficits, or Theory of Mind deficits. The Reading the Mind in the Eyes task (abbreviated as the Eyes task) was developed to assess the mindreading deficits as a hallmark of social deficits of ASD. This study aims to investigate the ability of reading emotions by the Eyes task in adults with ASD, and examine the gazing pattern and frontal activation during the task. We plan to recruit 50 adults with ASD and 50 typically-developing adults. All the participants will complete clinical measures and the Eyes task. Eye-tracking and frontal activation (measured by functional near-infrared spectroscopy) will be examined during the Eyes task.

Eligibility criteria: Inclusion Criteria:

* Adult aged between 20 and 50 years who had a diagnosis of ASD based on DSM-5.
* Had a full-scale IQ \> 70 on WAIS-IV.

Exclusion Criteria:

* A history of major mental illness (e.g., bipolar affective disorder, schizophrenia) or neurological diseases.
* Visual impairment and that would preclude participation.

Primary outcomes:
measure: eye tracking indicators
timeFrame: 30 min
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Yi Ling Chien, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01575509: A Comparative Study of Effects of Berry and Grain Products on Postprandial Glycemic Response in Healthy Subjects
Official title: A Clinical, Randomized, Comparative Study of Effects of Berry and Grain Products on Postprandial Glycemic Response in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: Clinical Life Sciences Ltd.
Sponsor class: OTHER
Collaborators: name: Kiantama Oy
name: Suomen Sokeri Oy
First posted: 2012-04-11
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: This study aims to determine the 2 hour glycemic responses of two bread products and one dried lingonberry product. The average postprandial response of each product is compared with glycemic response after ingestion of control solution with a similar carbohydrate content (glucose, glucose-fructose) as the provided by the respective test product.


Eligibility criteria: Inclusion Criteria:

* voluntary given written concent for participation in research
* healthy man or woman, age between 18 and 65 years
* regular eating
* Body Mass Index 18,5 - 29,9 kg/m2

Exclusion Criteria:

* diabetes
* gastrointestinal diseases
* hepatic, kidney, pancreas or thyroid disease or disorder
* arthritis
* pregnancy or breast feeding
* smoking
* allergy
* severe diseases
* blood donation

Primary outcomes:
measure: The 2 hours glycemic responses to test products and control solutions
timeFrame: 2 hours
Secondary outcomes:
measure: The 2 hours insulinemic responses to dried lingonberry product and corresponding control solution
timeFrame: 2 hours
measure: The incremental area under glucose curve (IAUC) of bread test products
timeFrame: 2 hours
measure: Glycemic index (GI) of bread test products
Other outcomes:
Locations:
city: Kajaani
country: Finland
facility: Clinical Life Sciences Ltd
Study officials:
name: Päivi Cheney, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01095809: Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema
Official title: Open , Randomized Study About Efficacy, Safety and Tolerability od Repeated Dosis of Intravitreous Bevacizumab in Patients With Uveitic Macular Oedema
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Uveitis
Lead sponsor: Hospital Clinic of Barcelona
Sponsor class: OTHER
First posted: 2010-03-30
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether intravitreous bevacizumab or intravitreous triamcinolone acetonide are effective and safe in the treatment of uveitic macular oedema


Eligibility criteria: Inclusion Criteria:

* adult patients with uveitis or retinal vasculitis with unilateral or bilateral macular oedema
* with macular thickness \> 250 micra using OCT
* visual acuity at least 20/200
* with stable treatment with oral prednisone at least during 3 months, either oral ciclosporin or other immunomodulator to treat intraocular inflammatory disease
* patient that can follow study's requirements
* patient who consents to participate

Exclusion Criteria:

* presence of corneal or crystalline opacity preventing observation of fundus of eye
* patients requiring ocular surgery in next 3 months
* one-eyed
* pregnancy and child breastfeeding
* previous history of glaucoma
* on treatment woth an experimental ocular drug
* previous thromboembolism or receiving oral anticoagulant treatment
* vitrectomy
* patients with proved tractional macular pathology associated to macular oedema

Primary outcomes:
measure: Macular Thickness Measurements Using Stratus Optical Coherence Tomography
timeFrame: 48 weeks
Secondary outcomes:
measure: visual acuity
timeFrame: 48 weeks
measure: intraocular pressure
timeFrame: 48 weeks
measure: opacity crystalline
timeFrame: 48 weeks
Other outcomes:
Locations:
city: palma de Mallorca
country: Spain
facility: Hospital de Son Dureta
state: Spain/ Baleares
city: Barcelona
country: Spain
facility: Hospital Santa creu i Sant Pau
state: Spain/ catalonia
city: Alicante
country: Spain
facility: Instituto Vissum Alicante
state: Spain/ Com. Valenciana
city: Barcelona
country: Spain
facility: Hospital Vall d'Hebron
state: Spain/Catalonia
city: Barcelona
country: Spain
facility: Hospital Clinic of Barcelona
state: Spain/Catalonia
Study officials:
References: